Lu177-pentixather

Lu177-pentixather is a targeted radiopharmaceutical therapy that combines the CXCR4-targeting peptide PentixaTher with the beta-emitting radioisotope lutetium-177. It is designed to deliver localized radiation to malignant cells expressing the chemokine receptor CXCR4, which is overexpressed in various hematologic and solid tumors. The drug acts as a theranostic agent, leveraging its high affinity and selectivity for human CXCR4 to achieve high tumor uptake and retention, resulting in effective tumor irradiation while sparing surrounding healthy tissue. Preclinical and early clinical studies have demonstrated promising results in multiple myeloma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), T-cell lymphoma, and other cancers. The primary developer of this agent is Pentixapharm.

Brand names

Lu177-PentixaTherLu-177-PentixaTherLu 177-PentixaTher

Other names

[^177Lu]pentixatherLutetium 177 pentixatherLutetium177 pentixatherLutetium-177 pentixather